ARDX maybe far better than GERN, because: 1) ARDX is selling two already approved and fast selling drugs with market potential at peak 3 times GERN's, though its stock market capitalization is only 2 times GERN's; 2) GERN's imetelstat has not been approved yet, and thus has lots of uncertainty.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.